
Abivax (ABVX) fell over 9% in Friday’s trading session after a short report from Scorpion Capital called the company a “biotech fraud for the ages,” alleging, among other things, that
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| ABVX | Abivax SA Sponsored ADR | 73.20 | -45.92 | -38.55% |
| Name | Price | % Change | |
|---|---|---|---|
| $73.20 | -38.55% |

Abivax (ABVX) fell over 9% in Friday’s trading session after a short report from Scorpion Capital called the company a “biotech fraud for the ages,” alleging, among other things, that

Abivax (ABVX) ssued a statement regarding a report published by Scorpion Capital on November 20, 2026, “We are reviewing the Scorpion Capital report in detail and anticipate providing further updates

Abivax (ABVX) is down -12.0%, or -$9.66 to $70.99. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on

Analyst Julian Harrison of BTIG reiterated a Buy rating on Abivax SA Sponsored ADR, retaining the price target of $175.00. Julian Harrison has given his Buy rating due to a

The major averages were mixed near noon, with the Dow falling almost 300 points but the Nasdaq climbing nearly 100 points as oil prices eased fractionally following yesterday’s sharp decline.

Wedbush lowered the firm’s price target on Abivax (ABVX) to $118 from $140 and keeps a Neutral rating on the shares. The firm notes the company reported Q2/first half of

Truist lowered the firm’s price target on Abivax (ABVX) to $151 from $155 and keeps a Buy rating on the shares. The firm is updating its model while noting that

Fabio Cataldi, M.D., Chief Medical Officer, will be leaving Abivax (ABVX) in Q4. Chris Rabbat, Ph.D., who has led Global Medical Affairs since 2023, will succeed Cataldi as Chief Medical

Pre-earnings options volume in Abivax (ABVX) is normal with calls leading puts 10:9. Implied volatility suggests the market is anticipating a move near 6.0%, or $6.21, after results are released.

Abivax SA Sponsored ADR (ABVX) is scheduled to report 2nd quarter earnings on 09/21/2026. Regarding Q2 estimates, Wall Street analysts expect Abivax SA Sponsored ADR to post earnings of -$0.92
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Oct 21, 2026 | ||||
| buy | Reiterated | Oct 20, 2026 | ||||
| buy | Reiterated | Oct 20, 2026 | ||||
| buy | Reiterated | Oct 1, 2026 | ||||
| buy | Reiterated | Sep 28, 2026 | ||||
| buy | Reiterated | Sep 22, 2026 | ||||
| buy | Reiterated | Sep 22, 2026 | ||||
| hold | Reiterated | Sep 22, 2026 | ||||
| buy | Initiated | Sep 9, 2026 | ||||
| buy | Upgraded | Jul 1, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Dec 14, 2026TBA | $7.31B | $-0.92 | $923.00K | -0.37 | -13.38 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.